SCHEMBL25447066

SCHEMBL25447066

CC(C)(C)N1CCC(c2ccc(C3CCC(=O)NC3=O)cc2F)CC1

nearest known ligand 0.46

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 19/20 0.46
▸ DDB1 Q16531 18/20 0.46
▸ POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24873036 0.87 CRBN (0.53) CRBNDDB1POLB
SCHEMBL26329328 0.84 CRBN (0.46) CRBNDDB1POLB
SCHEMBL25447065 0.83 CRBN (0.55) CRBNDDB1POLB
SCHEMBL24881088 0.83 DDB1 (0.63) CRBNDDB1POLB
SCHEMBL29877042 0.83 DDB1 (0.63) CRBNDDB1POLB
SCHEMBL29877207 0.82 CRBN (0.51) CRBNDDB1POLB
SCHEMBL24125789 0.82 CRBN (0.51) CRBNDDB1POLB
SCHEMBL29977325 0.81 CRBN (0.53) CRBNDDB1POLB
SCHEMBL24124611 0.81 CRBN (0.53) CRBNDDB1POLB
SCHEMBL24881395 0.81 CRBN (0.42) CRBNDDB1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025049820-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2025-03-06 — — WO disclosed
US-20230145336-A1 BRAF DEGRADERS C4 THERAPEUTICS, INC. (US) 2023-05-11 — — US disclosed
US-20230145336-A1 BRAF DEGRADERS C4 THERAPEUTICS, INC. (US) 2023-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230145336-A1 BRAF DEGRADERS BRAF, NRAS, RAF1 CRBN 249/4885DDB1 368/4885POLB 698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback